AR112402A1 - Dihidrooxadiazinonas - Google Patents

Dihidrooxadiazinonas

Info

Publication number
AR112402A1
AR112402A1 ARP180102218A AR112402A1 AR 112402 A1 AR112402 A1 AR 112402A1 AR P180102218 A ARP180102218 A AR P180102218A AR 112402 A1 AR112402 A1 AR 112402A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
optionally substituted
independently selected
substituents
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Alex Burgin
Meyerson Matthew Prof
Xiaoyun Wu
Heidi Greulich
Timothy A Lewis
Slzle Detlev Dr
Dr Hegele-Hartung Christa Prof
Lienau Philip Dr
Tersteegen Adrian Dr
Lange Martin Dr
Kopitz Charlotte Christine Dr
Gradl Stefan Nikolaus Dr
Ellermann Manuel Dr
Original Assignee
Bayer Ag
Bayer Pharma AG
Broad Inst Inc
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG, Broad Inst Inc, Dana Farber Cancer Inst Inc filed Critical Bayer Ag
Publication of AR112402A1 publication Critical patent/AR112402A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/04—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP180102218 2017-08-04 2018-08-03 Dihidrooxadiazinonas AR112402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762541627P 2017-08-04 2017-08-04

Publications (1)

Publication Number Publication Date
AR112402A1 true AR112402A1 (es) 2019-10-23

Family

ID=63207725

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102218 AR112402A1 (es) 2017-08-04 2018-08-03 Dihidrooxadiazinonas

Country Status (26)

Country Link
US (3) US11427553B2 (enExample)
EP (1) EP3661517B1 (enExample)
JP (2) JP7676141B2 (enExample)
KR (1) KR20200036914A (enExample)
CN (1) CN111212647B (enExample)
AR (1) AR112402A1 (enExample)
AU (1) AU2018309356B2 (enExample)
BR (1) BR112020002351A2 (enExample)
CA (1) CA3071800A1 (enExample)
CL (1) CL2020000303A1 (enExample)
CO (1) CO2020001242A2 (enExample)
CR (1) CR20200057A (enExample)
CU (1) CU24608B1 (enExample)
EA (1) EA202090448A1 (enExample)
EC (1) ECSP20008441A (enExample)
IL (1) IL272098B2 (enExample)
JO (1) JOP20200024A1 (enExample)
MA (1) MA49750A (enExample)
MX (1) MX2020001404A (enExample)
PE (1) PE20200936A1 (enExample)
PH (1) PH12020500134A1 (enExample)
SG (1) SG11201913775UA (enExample)
TW (1) TWI791581B (enExample)
UA (1) UA125731C2 (enExample)
UY (1) UY37832A (enExample)
WO (1) WO2019025562A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
TW202031677A (zh) 2018-11-01 2020-09-01 美商博得學院股份有限公司 Pde3調節劑反應性癌症之鑑定
WO2020157188A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Dihydrooxadiazinones for the treatment of hyperproliferative diseases
AU2020215088A1 (en) 2019-02-01 2021-07-22 Bayer Aktiengesellschaft 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases
CN117279644A (zh) 2021-03-03 2023-12-22 拜耳股份有限公司 用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮
EP4289828A1 (en) 2022-06-10 2023-12-13 Bayer Aktiengesellschaft Method for the preparation of a 3,6-dihydro-2h-1,3,4-oxadiazin-2-one
EP4289829A1 (en) 2022-06-10 2023-12-13 Bayer Aktiengesellschaft Crystalline forms of (6s)-5-[4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro- 2h-1,3,4-oxadiazin-2-one
CN120187704A (zh) * 2022-11-24 2025-06-20 盛睿泽华医药科技(苏州)有限公司 吡啶酮化合物及其制备方法和用途
CN117903077B (zh) * 2023-01-13 2024-09-03 上海超阳药业有限公司 二氢噁二嗪酮化合物及其应用
CN118420559B (zh) * 2023-04-27 2025-02-14 上海超阳药业有限公司 氘代噁二嗪酮化合物及其用途
CN118047833B (zh) * 2024-01-31 2025-03-14 海南大学 含二茂铁的取代氨基乙酰胺类化合物及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097671A (en) * 1975-08-28 1978-06-27 General Electric Company Dihydrooxadiazinones and method for making
US4052395A (en) 1975-09-11 1977-10-04 Sankyo Company Limited Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones
US4258094A (en) * 1979-04-26 1981-03-24 Brunswick Corporation Melt bonded fabrics and a method for their production
US4334030A (en) 1979-11-23 1982-06-08 General Electric Company Thermoplastic foamable blends
DE3172252D1 (en) 1980-11-14 1985-10-17 Ici Plc Heterocyclic compounds
DE3263497D1 (en) 1981-03-04 1985-06-20 Ciba Geigy Ag Pyridazinones, method for their preparation, pharmaceutical compositions containing these compounds and their use
ZA827641B (en) 1981-11-12 1983-09-28 Ici Plc Thiadiazine, oxadiazine and triazine derivatives which possess cardiotonic and/or antihypertensive activity
US4495185A (en) 1981-11-12 1985-01-22 Imperial Chemical Industries, Plc 1,2,4-Triazin-3(2H) ones
US4581356A (en) 1983-03-22 1986-04-08 Fujisawa Pharmaceutical Co., Ltd. Triazine derivatives, and pharmaceutical compositions comprising the same
GB8310435D0 (en) 1983-04-18 1983-05-25 Fujisawa Pharmaceutical Co Triazine derivatives
JPS59196874A (ja) 1983-04-22 1984-11-08 Fujisawa Pharmaceut Co Ltd トリアジン誘導体
JPS6153270A (ja) 1984-08-17 1986-03-17 チバ・ガイギー・アクチエンゲゼルシヤフト 置換ピリダジノン、その製造方法及び該化合物を含む医薬製剤
US4816454A (en) 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
GB8426804D0 (en) 1984-10-23 1984-11-28 Ciba Geigy Ag Pyridazinones preparations
DE3677316D1 (de) 1985-10-17 1991-03-07 Smith Kline French Lab 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl-derivate.
EP0303418A3 (en) 1987-08-11 1990-11-07 Smithkline Beecham Laboratoires Pharmaceutiques Substituted indolones, useful in the treatment of heart or asthmatic diseases
ATE180475T1 (de) 1990-09-21 1999-06-15 Rohm & Haas Dihydropyridazinone und pyridazinone als fungizide
JPH0676325B2 (ja) * 1992-05-08 1994-09-28 三井東圧化学株式会社 オキサジアジン誘導体を有効成分として含有する抗血栓剤
JPH07508987A (ja) 1992-07-01 1995-10-05 オーソ・フアーマシユーチカル・コーポレーシヨン 1−アリールスルホニル,アリールカルボニルおよび1−アリールホスホニル−3−フェニル−1,4,5,6−テトラヒドロピリダジン
JPH07291968A (ja) 1994-04-26 1995-11-07 Mitsubishi Chem Corp トリアジノン誘導体またはその塩類
DE19929787A1 (de) * 1999-06-29 2001-01-04 Bayer Ag Neue 4-(2-Oxodihydrooxadiazinylphenyl)amide und ihre Verwendung
EP1368035A1 (en) * 2001-02-12 2003-12-10 MERCK PATENT GmbH Use of type 4 phosphodiesterase inhibitors in myocardial diseases
WO2008108602A1 (en) 2007-03-07 2008-09-12 Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
CA2758774C (en) 2009-04-15 2015-02-03 Research Triangle Institute Monoamine reuptake inhibitors
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5794297B2 (ja) 2010-05-07 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Gpr119アゴニストとしてのピリダジノン
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
WO2014164704A2 (en) 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
WO2017027854A1 (en) * 2015-08-13 2017-02-16 The Broad Institute, Inc. Compositions and methods for cancer expressing pde3a or slfn12
US10729680B2 (en) 2016-01-14 2020-08-04 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
TW201733591A (zh) 2016-02-05 2017-10-01 拜耳製藥公司 用於癌症病人分級及癌症治療之化合物、組合物及方法
KR101831772B1 (ko) * 2016-03-24 2018-03-06 아이디에스(주) 복합 광원 모듈을 가지는 카메라 접사용 기구 및 이를 이용한 지문 시편 촬영 방법
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
TW202031677A (zh) 2018-11-01 2020-09-01 美商博得學院股份有限公司 Pde3調節劑反應性癌症之鑑定
AU2020215088A1 (en) 2019-02-01 2021-07-22 Bayer Aktiengesellschaft 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
CU20200008A7 (es) 2020-11-30
KR20200036914A (ko) 2020-04-07
WO2019025562A1 (en) 2019-02-07
US11773070B2 (en) 2023-10-03
PE20200936A1 (es) 2020-09-17
IL272098A (en) 2020-03-31
CL2020000303A1 (es) 2020-11-13
CR20200057A (es) 2020-06-16
EP3661517B1 (en) 2023-09-13
CN111212647B (zh) 2024-05-14
CO2020001242A2 (es) 2020-02-18
US12258323B2 (en) 2025-03-25
UY37832A (es) 2019-02-28
US11427553B2 (en) 2022-08-30
PH12020500134A1 (en) 2021-01-25
CN111212647A (zh) 2020-05-29
AU2018309356A1 (en) 2020-01-30
CA3071800A1 (en) 2019-02-07
ECSP20008441A (es) 2020-05-29
JP2023115065A (ja) 2023-08-18
BR112020002351A2 (pt) 2020-09-08
MX2020001404A (es) 2020-03-12
JOP20200024A1 (ar) 2020-02-02
MA49750A (fr) 2020-06-10
IL272098B1 (en) 2023-03-01
TWI791581B (zh) 2023-02-11
TW201917126A (zh) 2019-05-01
JP7676141B2 (ja) 2025-05-14
EP3661517A1 (en) 2020-06-10
US20220396554A1 (en) 2022-12-15
AU2018309356B2 (en) 2022-12-15
JP2020529439A (ja) 2020-10-08
CU24608B1 (es) 2022-06-06
SG11201913775UA (en) 2020-01-30
EA202090448A1 (ru) 2020-05-21
UA125731C2 (uk) 2022-05-25
IL272098B2 (en) 2023-07-01
US20200369633A1 (en) 2020-11-26
US20230017200A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
AR109805A1 (es) Derivados de oxadiazol microbiocidas
AR116109A1 (es) Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR111807A1 (es) Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
AR113929A1 (es) Compuestos heterocíclicos
AR108130A1 (es) Derivados de pirazolopirimidina
AR111279A1 (es) Derivados heterocíclicos útiles como inhibidores duales de atx / ca
AR100059A1 (es) Compuestos útiles como inmunomoduladores
AR095508A1 (es) 4-amino-6-(heterocíclico)picolinatos y 6-amino-2-(heterocíclico)pirimidina-4-carboxilatos y su uso como herbicidas
AR099955A1 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
AR092973A1 (es) Benzamidas
AR089207A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR110789A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
AR112283A1 (es) Uso de derivados de aminoalquilbenzotiazepina
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR098311A1 (es) Compuestos para el control de artrópodos
AR110790A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
AR116464A1 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
AR116558A1 (es) Oxadiazoles
AR114465A1 (es) Compuestos de pirazol sustituidos con heteroarilo y su utilización farmacéutica
AR091516A1 (es) Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
AR088610A1 (es) Compuestos plaguicidas
AR096490A1 (es) Moduladores del receptor cxcr7

Legal Events

Date Code Title Description
FA Abandonment or withdrawal